05/08/2024 16:00 |
Notice Regarding the Recording of Non-Operating Income (Foreign Exchange Income) |
05/08/2024 16:00 |
Consolidated Financial Results for the Three Months Ended March 31, 2024 [Japanese GAAP] |
05/08/2024 16:00 |
Financial Results for the Three Months Ended March 31, 2024 |
05/07/2024 15:00 |
Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101 |
04/30/2024 15:00 |
Modalis Therapeutics to Present Data Supporting Development of Transformative Epigenome Editing Medicines for the Treatment of Muscular Dystrophy |
04/15/2024 15:00 |
Modalis Therapeutics to Present Data Supporting Development of Transformative Epigenome Editing Medicines for the Treatment of Muscular Dystrophy |
04/12/2024 15:00 |
Modalis Announces Partnership with Ginkgo Bioworks |
04/12/2024 15:00 |
Modalis Announces updated strategic plan and business consolidation of US operation |
03/12/2024 15:00 |
Notice of Change in a Major Shareholder |
03/05/2024 08:00 |
Notice of 2024 Annual General Meeting and Meeting Materials |
02/22/2024 15:00 |
Announcement on Reduction in Amounts of Stated Capital and Capital Reserves and Appropriation of Other Capital Surplus |
02/14/2024 15:00 |
Notice Regarding the Variance between consolidated results and results of the previous year, non-consolidated results and results of the previous year |
02/14/2024 15:00 |
Notice Regarding the Recording of Non-Operating Income (Foreign Exchange Income), Extraordinary Income and Extraordinary Loss |
02/14/2024 15:00 |
Financial Results for the Fiscal Year Ended December 31, 2023 |
02/14/2024 15:00 |
Consolidated Financial Results for the Fiscal Year Ended December 31, 2023 [Japanese GAAP] |
12/13/2023 08:30 |
Modalis and JCR Pharmaceuticals enter into joint research agreement |
11/07/2023 16:00 |
Notice Regarding the Recording of Non-Operating Income and Extraordinary Loss |
11/07/2023 16:00 |
Financial Results for the Nine Months Ended September 30, 2023 |
11/07/2023 16:00 |
Consolidated Financial Results for the Nine Months Ended September 30, 2023 [Japanese GAAP] |
08/07/2023 15:00 |
Financial Results for the Six Months Ended June 30, 2023 |
08/07/2023 15:00 |
Notice Regarding the Recording of Non-Operating Income and Extraordinary Loss |
08/07/2023 15:00 |
Consolidated Financial Results for the Six Months Ended June 30, 2023 [Japanese GAAP] |
08/07/2023 15:00 |
Business Plans and Matters Related to High Growth Potential |
08/07/2023 15:00 |
Notice of pipeline consolidation |
08/07/2023 15:00 |
Modalis Therapeutics to Regain Full Rights to DM1 and DMD Programs |
07/05/2023 17:00 |
Notice Regarding Determination of Terms and Conditions of Stock Options (Share Acquisition Rights) |
06/26/2023 08:45 |
Modalis Receives Positive FDA Response for Pre-IND Review For MDL-101 Clinical Development |
06/15/2023 16:30 |
Notice Regarding Issuance of Stock Options (Share Acquisition Rights) |
05/22/2023 15:00 |
Presentation of Data Supporting of Development of Transformative Epigenetic Editing Medicines at the ASGCT Annual Meeting |